The report found the therapy boosted rates of transfusion independence, particularly among patients who had a low baseline transfusion rate.
Luspatercept (Reblozyl; Bristol Myers Squibb) can reduce the need for red blood cell transfusions among people with lower-risk myelodysplastic syndromes (LR-MDS), according to a new report.
The study, published in HemaSphere, found the therapy had similar efficacy in real-world usage as it did in its pivotal clinical trials.
The authors wrote that anemia is the most common cytopenia in patients with LR-MDS, and the majority of those patients require red blood cell transfusions. Severe anemia and transfusion dependency have both been linked with a shorter overall survival, they added.
One therapeutic option for these patients, the authors said, is luspatercept, an erythroid maturation agent that improves both the number and quality of mature red blood cells.
Last year, the FDA approved the therapy for patients with very low- to intermediate-risk MDS who require regular transfusions of red blood cells.
In the new report, investigators decided to analyze real-world data to find out how luspatercept was being used and to characterize its clinical outcomes.
The researchers used an electronic case report database to locate deidentified cases of adult patients who had been diagnosed with very low-, low-, or intermediate-risk MDS confirmed by bone marrow biopsy on or after January 1, 2015, and who had been given at least 12 weeks of luspatercept. The primary outcome was transfusion independence or maintenance of non–transfusion-dependent status for at least 8 weeks during the first 24 weeks on luspatercept. The authors also tracked whether patients had a decrease in the number of transfusion sessions they needed.
They identified a total of 253 cases that met the study’s inclusion criteria. Most of those patients (82.2%) had a low transfusion burden at baseline, meaning they required 1 to 3 red blood cell sessions and/or platelet sessions during the 8 weeks prior to initiation of luspatercept. A similar majority of the patients (86.6%) had already received 1 line of treatment, and 12.3% had received 2 or 3 lines of treatment prior to luspatercept initiation. The most common prior therapy utilized by the patients was erythropoiesis stimulating agents.
All patients started luspatercept at the recommended dose of 1 mg/kg every 3 weeks. The majority of patients (61.3%) had no dose escalations, and most (93.7%) had no dose reductions.
The authors noted that one-third of patients discontinued luspatercept, but 57 of those 84 patients did so when they were receiving less than the maximum recommended dose.
At a median follow-up of 5.7 months, most of the patients (87.4%) achieved transfusion independence or maintained non–transfusion-dependent status for at least 8 weeks.
Broken up by baseline transfusion burden, the authors found that 89.9% of the 208 patients who had a low baseline transfusion burden achieved treatment independence for at least 8 weeks, and the remaining 21 patients maintained the low transfusion burden status for at least 8 weeks. Among the 24 patients with moderate transfusion burden (4-5 red blood cell sessions and/or platelet sessions during the 8 weeks prior to initiation of luspatercept), the transfusion independence rate was slightly lower, at 58.3%, with all of the remaining patients achieving low transfusion burden for the first 8 weeks of luspatercept.
The authors noted that their findings line up with the results of the trials upon which the FDA’s approvals were based, showing that luspatercept can promote transfusion independence among people with low or moderate transfusion dependence at baseline.
“These data extend evidence from the MEDALIST trialand COMMANDS trial in support of the continued, robust clinical benefit of luspatercept in patients with LR‐MDS who are [transfusion dependent],” they wrote.
Reference:
Mukherjee S, Brown-Bickerstaff C, Falkenstein A, et al. Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: a retrospective US cohort analysis. Hemasphere. 2024;8(1):e38. doi:10.1002/hem3.38
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Patients With COPD, PRISm at Increased All-Cause, Cause-Specific Mortality Risk
May 20th 2024Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need for better understanding of these conditions through increased spirometry data collection.
Read More